AMDL Launches Expanded Distribution With 4th Round of Agreements Valued at $6.79 Million Annually for New Health & Beauty Product Line
JJB has signed three new Central Region exclusive, one-year renewableDistribution and Agency Agreements that were signed between Jade Pharma'ssubsidiary JJB and Henan Yinji Bio-chemistry Co., Ltd. ("HYB"), ChengduFairyland Cosmetics Co., Ltd. and ("CFC"), Guizhou Camry Beauty TechnologyCo., Ltd. ("GCB"). These agreements cover the key cities in Henan, Sichuan andGuizhou Provinces that have a combined population of approximately 134.4million people. These two separate agreements in combination, require thesenew distributors to purchase a minimum of US$6,790,944 of JJB's new HPHproduct during the one-year period of the contracts and a minimum initialorder of US$4,061,250.
Frank Zheng, managing director of JPI, said this fourth round ofadditional distribution agreements, coupled with the previously announcedagreements, puts the Company on the path to building sales of Goodnak by asmuch as $24 million over the next 12 months. Gary Dreher, CEO of AMDL said theCompany expects to further update the market on its expansion plans in thecoming weeks.
About Goodnak: Goodnak is a high quality injectable anti-aging & skin careproduct that contains an amalgam of various therapeutic elements includinghuman placental histosolution ("HPH"). JPI has begun selling Goodnak, inAugust, through wholesale distribution channels that service high-end beautysalon and plastic surgery hospitals and or medical cosmetology institutions.Goodnak product information is available on Jade Pharma's product specificwebsite: http://www.jade-amdl.com.
About JPI: Jade Pharmaceutical through its subsidiaries JJB & YYB hasaccess to the fastest growing pharmaceutical and consumer market in the world:China. AMDL, through its subsidiary, Jade currently manufactures large volumeinjectable fluids, tablets and other related products, holding licenses for133 products. It also manufactures 107 generic, over the counter andsupplemental pharmaceutical products under certified Chinese GoodManufacturing Practice (CGMP) standards.
About AMDL: More information about AMDL and its products can be obtainedat http://www.amdl.com.
Forward-Looking Statements: This news release contains forward-lookingstatements within the meaning of the Private Securities Litigation Reform Actof 1995. Such statements are subject to certain risks and uncertainties, andactual circumstances, events or results may differ materially from thoseprojected in such forward-looking statements. The Company cautions readers notto place undue reliance on any forward-looking statements. The Company doesnot undertake, and specifically disclaims any obligation, to update or revisesuch statements to reflect new circumstances or unanticipated events as theyoccur.Contact: AMDL, Inc. Mr. Paul Knopick AMDL Investor Relations Direct Line: 949.707.5365 VoiceMail: 714.505.4460
SOURCE AMDL, Inc.
You May Also Like